Avita Medical, Inc.

As of June 30, 2026, Avita Medical, Inc. carries a market capitalization of 127.73M, placing it among publicly traded companies globally. Its enterprise value stands at 165.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Avita Medical, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Avita Medical, Inc. has 30.93M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.64, and the price-to-book ratio stands at -4.59.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 165.07M versus a market cap of 127.73M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Avita Medical, Inc. maintains a current ratio of 0.41, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -174.15, indicating conservative leverage, while an interest coverage ratio of -6.05 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -81.36, reflecting losses generated across the asset base. The company generates approximately 322,515.99 in revenue per employee across its workforce of 234.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.18 indicates how many times Avita Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Avita Medical, Inc. recorded 20,000.00 in income tax expense. The company reported a pretax loss of -43.06M and -43.08M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Avita Medical, Inc.'s stock has gained approximately 289.39% over the past 52 weeks. The 50-day moving average sits at 11.38, while the 200-day moving average is 6.18.

Over the twelve months ended June 30, 2026, Avita Medical, Inc. generated 75.63M in revenue and converted that into -43.08M in net income, yielding earnings per share of -1.44. EBITDA reached -32.71M, while operating income came in at -35.22M.

As of June 30, 2026, Avita Medical, Inc. holds 11.14M in cash and equivalents against 48.48M in total debt, resulting in a net debt position of 37.52M. Total book value stands at -27.84M, with working capital of -40.32M providing operational flexibility.

Avita Medical, Inc. produced -24.22M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -479,000.00 in capital expenditures, free cash flow totaled -24.70M - equivalent to -0.82 per share.

Over the twelve months ended June 30, 2026, Avita Medical, Inc. posted a gross margin of 81.56, reflecting its pricing power and cost economics. The operating margin of -46.57 and net profit margin of -56.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.93: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.09, meaning Avita Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Avita Medical, Inc.'s most recent stock split took place on June 30, 2020 with a 5:1 split ratio.

As of June 30, 2026, Avita Medical, Inc. has an Altman Z-Score of -15.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.